Ticiana Leal, MD - Translating Trials to Treatment: Practical Strategies for Immunotherapy Integration in Limited-Stage and Extensive-Stage SCLC

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

2026-09-24- KSR - Hour 1 1h 4m · 24 Sep 2026 · KSR

Football vs jetlag | Who is the Mayo of the NFL? | Super Bowl favourites | Hockey's coaching scandal | US Sports Roundtable 1h 11m · 24 Sep 2026 · Indo Sport

Is This The October Surprise? (Ep. 2602) 1h 30m · 24 Sep 2026 · The Dan Bongino Show

Sage Advice From Granny Bingo 19 min · 24 Sep 2026 · It's A Lot with Abbie Chatfield

Trump, Xi Begin State Visit, Oil Soars on Iran Threat, More 7 min · 24 Sep 2026 · Bloomberg News Now

The Single Dumbest Thing Ever Said About the Miami Heat | Hour 2 37 min · 24 Sep 2026 · The Dan Le Batard Show

Report any issue

Source

Recorded08 Jan 2026

Publisherc.answersincme.com ↗

Handlerec:15207521

Show notes

Please visit answersincme.com/JRV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lung cancer discusses the use of immunotherapy in clinical practice for patients with limited-stage (LS) and extended-stage (ES) small-cell lung cancer (SCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of immune checkpoint inhibitors in LS-SCLC and ES-SCLC; Assess the clinical profiles of approved and emerging immune checkpoint inhibitor therapies for LS-SCLC and ES-SCLC; and Outline evidence-based strategies for incorporating immune checkpoint inhibitor therapy into treatment plans for patients with LS-SCLC and ES-SCLC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in